Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
Status:
Withdrawn
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to compare the safety and effectiveness of standard
treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin
(Copegus) to those same medications plus a dietary supplement called betaine when added for
the first 12 weeks of treatment.
Peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) are approved by the FDA (Food and
Drug Administration) for the treatment of chronic hepatitis C.
Betaine is a dietary supplement and occurs naturally in the body. It is not a medication
regulated by the FDA or an approved drug for chronic hepatitis C.